The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Dallo,
I think WE all agree on the future potential in Incanthera and IMM.
WE are knit picking but there is a Big différence between what IS in Imm accounts AT this Time and what there will be in the future IF they exercice the warrants.
Imm need Cash to exercice these warrants .
Have a look AT the COMPANY accounts to and the BOOK values before stating that i am mistaken 'once AGAIN ''
Looking forward to the growth of imm.
I feel an update on Lupuzor are due
Hi Dallo, I agree with you, combining the value of the direct shares and the potential from the warrants can result in a net unrealised gain for ImmuPharma, especially considering the upside potential of the warrants.
Let's delve into how these warrants could significantly contribute to ImmuPharma's value, especially with Incanthera's growth trajectory and potential acquisition scenarios.
Understanding the Warrants
ImmuPharma holds 7.3 million warrants in Incanthera, exercisable at any time, which is a testament to ImmuPharma's strategic investment acumen. These warrants represent a right but not an obligation to purchase additional shares at a predetermined price, in this case, 9.5p. Given Incanthera's top share price of 18p this morning, these warrants already hold considerable unrealised value.
Current Value and Future Potential
-Current Value Analysis:
Incanthera Share Price: 18p
Warrant Exercise Price: 9.5p
Difference: 8.5p per share
With 7.3 million warrants, this difference suggests an immediate potential unrealized gain of approximately £620,500 for ImmuPharma, should these warrants be exercised at 18p. This calculation alone highlights the immediate upside potential.
-Future Growth Potential:
Incanthera's journey, particularly with its expanding portfolio and promising revenue projections, speaks volumes about its market potential. A takeover scenario, where Incanthera could be valued at, let's speculate, 100p per share, would dramatically increase the value of ImmuPharma's position.
Takeover Scenario Value:
Hypothetical Takeover Price: 100p
Gain per Warrant: 90.5p (after deducting the exercise price of 9.5p)
Total Gain from Warrants: £6,606,500 (Let's bear in mind the unused tax losses of £49,025,230 as of 31.12.2022 available for offset against future profits)
This speculative analysis does not just reflect the potential financial windfall but underscores the strategic importance of holding these warrants. The anticipation of Incanthera's growth, coupled with the biopharmaceutical sector's dynamism, where acquisitions are frequent for promising companies, makes this scenario a thrilling possibility.
Looking Ahead
ImmuPharma's investment in Incanthera, including its significant warrants holding, is a pivotal part of its long-term growth strategy. The biopharmaceutical industry is ripe with innovation and consolidation, making the potential for Incanthera's acquisition at a premium not just bullish but a plausible future event. This not only could result in substantial financial gains for ImmuPharma but also validate its strategic investment approach.
For long-term investors in ImmuPharma, this scenario paints a picture of significant upside potential, not just from its core operations but also from savvy investment decisions. The anticipated developments in Incanthera, from commercial success to possible acquisition offers, represent an exciting horizon.
This is my personal opinion, n
Dallo. I tried to say the same thing to him but looks like it fell on deaf ears !
" The outlook for the Incanthera share price based on the revenue forecasts is extraordinarily bullish"
Dallo
it is a great commercial deal .....but whilst I see significant revenue, the profit will be less significant simply because they will sub-contract the Manufacturing, quality control and packaging , which is to be expected ..plus the marketing and distribution costs which is being done by Incanthera's wholly owned new subsidiary
It really depends on volume and good repeat orders and the volume can come as the number of stockists increases
Profit I suspect will come through more in year 2 once the product has some established customer experience and initial marketing spend
This doubling of an initial order announcement is common... I think they probably set it up like that...I have seen that before on other new product launches to create the excitement of demand
A super client relationship with which to grow from though
This was up 55% on a RNS - which, whilst some loved - some said was a bit 'so-so'. Well whatever you think of this RNS just imagine what will happen if IMM release an RNS which is perceived as being unequivocally good - re trials and or licensing -then sp should go up more than 55%.
Nolupus
Have you not read the Incanthera RNS.
The warrants held by Immupharma represent an unrealised gain based on Incanthera's current SP.
The 9.9m direct holding is an unrealised loss.
The two Immupharma holdings, shares and warrants in Incanthera combined have a net unrealised gain.
This could change depending on Incanthera's SP.
The outlook for the Incanthera share price based on the revenue forecasts is extraordinarily bullish.
Even you must admit that the prospects for our investment in Incanthera looks excellent after today's update.
66 messages ,all means nothing except ,PRICE & VOLUME
ARE THE WARRANTS guaranteed cash ? I not up to date on warrants . SO tims company will pay imm the money? IMO they would need to be drip feed
Dallo,
My statement DID'nt ignore anything..
The warrants have no BOOK value as you know, until exercised ...
They may have the potential to make IMM Money if exercised but that cannot be guaranteed as yet
Goldgirl's posts - laughable
3 assets but 10m mcap
Laughable
5Rings
Here is to a great ride up lol
Https://www.share-talk.com/rns-hotlist-with-zak-mir-i3e-casp-imm-sol-cobr-knb-gcm-neo-mka-pow-uee-kefi-opti-lex-urah/
Marionnaud.
Comment: INC was and is a jewel in the crown for IMM. We should expect the company to revamp the enthusiasm seen surrounding the stock at the start of 2024 shortly.
Nolupus
Your statement ignores the value of Immupharma's 7.3 m warrants at 9.5p exercisable at any time in Incanthera.
I agree with GoldGirl. When IMM trial didn't go well likely due to patient selection not being precise, Tim as chairman and CEO faced the shareholders to explain was to be commended. They have a good solution which involves exquisite biomarkers. Don't know if anyone notice but this biomarker correlated with positive outcomes in pre-clinical also. This story is only getting better.
Imm invested £2.25 million into Incanthera and they are still on a papier loss on that investment AT this Time....
Dallo , as you are the "accountant", please let me know , what IS wrong With my statement ?
My posts seems to bother many of you 'strong buy' ' crowd but whatever, i won't be put off by any lies or diffamatory comments .
Nolupus at it again with wrong information that Immupharma's investment in Incanthera of £2.25m is still under water.
Not at todays Incanthera SP of 18p giving a value of Immupharma's 9.9 m shares in Incanthera at £1.8m plus current unrealised gain on the 7.3m warrants of c £700,000.
Incanthera looks like it will taken out soon by one of the big players given its forecast revenues for the next 2 years.
Now if only Tim could give us another juicy RNS on the commercial deals and Lupuzor trial data , we would be flying.
Goldgirl - you are a blatant ramper who is as bad as some of the de-rampers that post on here (they are obvs too). Can you post less pumped up drivel please. It is boring, and it doesn’t help it just becomes noise on here. 61 posts in a short period (before that HE1)
Ta
An ex-employee or somebody that has crossed swords with Tim McC in a past life?
Don't let him/her worry you-suggest you might filter.
GLA
the only question one should be asking is..
why the feck is nobinpus here posting all his pish when he has absolutely no financial investment in imm, zero not a single share in this company.
this type of behaviour is inappropriate, posting and arguing on a board with investors where you have zero investment in the company raises a lot of serious questions about an individual’s state of mind. it’s like me going over to a random message board and posting pish and ****e, it would be extremely inappropriate.
the only question one should be asking is..
why?
frits
For newbies
https://youtu.be/jR7I_0mkTM4?feature=shared
I need lunch now
Gla
TIM AS ceo
Pre-Tim Goldgirl????????
Tim has been Chairman of IMM for many years!
Admire your upbeat approach-but suggest a few minutes of background research would add to the credibility of your many recent contributions and to your knowledge.
Financial Upswing for ImmuPharma
Value Appreciation: ImmuPharma's 10.8% stake in Incanthera is poised for growth, fueled by Incanthera's notable commercial achievements. This uptick enhances ImmuPharma's financial outlook.
Warrant Holdings: ImmuPharma also holds 7.3 million warrants in Incanthera, providing a further opportunity to benefit from Incanthera's positive momentum.
Commercial Success and Strategic Expansion
Revenue Projection: Incanthera's forecasted revenues, growing from £10m in FY 2025 to £33m in FY 2026, denote a trajectory towards substantial profitability. This financial health reflects positively on ImmuPharma's strategic investment decisions.
Market Expansion: The recent commercial success of Incanthera's skincare deal with Marionnaud, marked by the rollout of Skin + CELL across European and potentially Asian stores, signifies not just a strong market demand but also shines a favorable light on Incanthera and, by extension, ImmuPharma. Given that Dr. Tim McCarthy serves as CEO for both ImmuPharma and Incanthera, this achievement could potentially open new doors for ImmuPharma. The visibility and industry connections gained through Incanthera's success might facilitate new contacts and partnership deals for ImmuPharma. This could enhance ImmuPharma's visibility in the biopharmaceutical sector, potentially leading to collaborations that could accelerate the development and commercialisation of its innovative therapeutic solutions.
Enhanced Stakeholder Confidence
Market Performance: The positive performance of Incanthera's stock, with a significant increase of 94%, not only bolsters investor confidence but also showcases the potential for further growth and the soundness of ImmuPharma's investment.
Portfolio Diversification: ImmuPharma's involvement with Incanthera diversifies its investment portfolio, mitigating risks and aligning with long-term growth strategies in both biopharmaceuticals and related sectors. Under Tim McCarthy's leadership, ImmuPharma has shown a strategic approach towards growth and diversification, especially evident in the Incanthera investment. This move, once heavily critiqued by some investors, is now demonstrating its value, illustrating McCarthy's foresight and deal-making acumen. The success with Incanthera not only reflects positively on McCarthy's vision but also promises to elevate ImmuPharma's standing, potentially opening new doors for partnership and visibility. As we witness these developments, it's clear that ImmuPharma is in a strong position, poised for progress, and in its best shape in years, despite current market valuations.
Looking ahead, ImmuPharma is well-positioned to enhance long-term shareholder value, embracing new opportunities and challenges with a strategic focus on sustainable growth.
Disclaimer: The above represents my personal opinion and should not be considered financial or investment advice.